Loading...

Brilliant Violet 510™ anti-mouse CD3 Antibody

Pricing & Availability
Clone
17A2 (See other available formats)
Regulatory Status
RUO
Other Names
T cell antigen receptor complex, T3
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
17A2_BV510_CD3_Antibody_FC_082312
C57BL/6 mouse splenocytes were stained with CD3 (clone 17A2) Brilliant Violet 510™.
  • 17A2_BV510_CD3_Antibody_FC_082312
    C57BL/6 mouse splenocytes were stained with CD3 (clone 17A2) Brilliant Violet 510™.
See Brilliant Violet 510™ spectral data
Cat # Size Price Quantity Check Availability Save
100233 125 µL 176 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100234 50 µg 274 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3, also known as T3, is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 is composed of CD3ε, δ, γ and ζ chains. It forms a TCR complex by associating with TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
γδTCR-positive T-T hybridoma D1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported application (for relevant formats) include: spatial biology (IBEX)1,2.

Application References

(PubMed link indicates BioLegend citation)
  1. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  2. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sordé L, et al. 2017. Immunity, Inflammation, and Disease. 10.1002/iid3.167. PubMed
  2. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  3. Landon J Edgar et al. 2018. Cell chemical biology. 26(1):131-136 . PubMed
  4. Zhang YS, et al. 2018. Cancer Biol Ther. 19:735. PubMed
  5. Wang F, et al. 2018. Carcinogenesis. 39:889. PubMed
  6. Bittner–Eddy PD, et al. 2017. Front Immunol. 1.304166667. PubMed
  7. Wang L, et al. 2019. Cell Rep. 29:1848. PubMed
  8. Ciecko AE, et al. 2019. Cell Rep. 29:3073. PubMed
  9. Cabrera-Perez C, et al. 2015. J Immunol . 194:1609-20. PubMed
  10. Cabrera-Perez J, et al. 2016. J Immunol. 197: 1692 - 1698. PubMed
  11. Hombrink P, et al. 2016. Nat Immunol. 17:1467-1478. PubMed
  12. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  13. Kuhn NF, et al. 2020. Nat Commun. 4.74375. PubMed
  14. Wijewarnasuriya D, et al. 2020. Cancer Immunol Res. 0.841666667. PubMed
  15. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  16. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  17. Okamoto T, et al. 2020. Cancer Res. 3580:80. PubMed
  18. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  19. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  20. Ren X, et al. 2021. Cell Death Dis. 12:484. PubMed
  21. Yang F, et al. 2021. Nat Commun. 12:3424. PubMed
  22. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  23. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  24. Menzel L, et al. 2021. Cell Rep. 37:109878. PubMed
  25. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  26. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  27. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  28. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  29. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  30. Bahmani B, et al. 2021. Nat Commun. 12:1999. PubMed
  31. Reyes RM, et al. 2021. Oncoimmunology. 10:2006529. PubMed
  32. Su Y, et al. 2022. J Hematol Oncol. 15:99. PubMed
  33. Mara AB, et al. 2022. NPJ Vaccines. 7:86. PubMed
  34. Qiu F, et al. 2022. J Cancer. 13:2893. PubMed
  35. Xiong A, et al. 2022. EBioMedicine. 83:104239. PubMed
  36. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  37. Orvain C, et al. 2022. Arthritis Res Ther. 24:13. PubMed
  38. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  39. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  40. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  41. Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed
  42. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  43. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  44. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  45. Yao RQ, et al. 2023. Mil Med Res. 10:27. PubMed
RRID
AB_2561387 (BioLegend Cat. No. 100233)
AB_2562555 (BioLegend Cat. No. 100234)

Antigen Details

Structure
Ig superfamily, CD3/TCR, 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
Antigen recognition, TCR signal transduction, T cell activation
Ligand/Receptor
Peptide antigen/MHC-complex
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12502 View all products for this Gene ID
UniProt
View information about CD3 on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account